Importantly, for the first time, we were able to show that in a PTEN-deficient prostate cancer model that displays p110α dominance (MSK-PCa3), selective inhibition of p110α (BYL719) resulted in feedback activation of PI3K signaling through p110β (Fig. 3c). Here, PTEN is linked to prostate cancer.